MIRA MIRA PHARMACEUTICALS, INC.
Price Chart
Executive Summary
MIRA Pharmaceuticals entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC, securing worldwide exclusive rights to its MIRA-55 and SKNY-1 development programs. The agreement consolidates the company's intellectual property portfolio under a unified global rights structure but does not materially modify previously disclosed core economic terms. This is a routine IP consolidation filing with no new material financial data disclosed.
Actionable Insight
This is a routine IP consolidation filing with no change in economics. The stock is unlikely to react materially. Monitor for IND filings for MIRA-55 and SKNY-1 as the next meaningful catalysts, as well as Phase 2a data for Ketamir-2.
Key Facts
- MIRA entered into an Amended and Restated Exclusive License Agreement with MIRALOGX LLC on June 3, 2026
- MIRA received worldwide exclusive rights to develop, manufacture, commercialize, and sublicense MIRA-55 and SKNY-1
- The amendment does not materially modify previously disclosed core economic terms
- MIRA-55 is an oral investigational drug candidate for chronic inflammatory pain; SKNY-1 is for obesity and addiction-related disorders
- Both candidates are preclinical-stage and have not been approved by the FDA
Financial Impact
No financial terms or economic consideration disclosed in the filing
Risk Factors
- Both MIRA-55 and SKNY-1 are preclinical investigational compounds with no FDA approval
- No new funding or partnership was announced alongside the license consolidation
- Company has a $42M market cap and is pre-revenue, making it sensitive to cash runway and dilution risk
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027202 |
| Exhibit: ex99-1.htm | 0001493152-26-027202 |
| Document: 0001493152-26-027202-index-headers.html | 0001493152-26-027202 |
| Document: 0001493152-26-027202-index.html | 0001493152-26-027202 |
| Document: 0001493152-26-027202.txt | 0001493152-26-027202 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
6d ago
|
8-K
| $1.01 awaiting T+1 | awaiting T+1 | — | $0.9400 (−6.47%) |
|
Jun 4, 2026
10d ago
|
8-K
| $1.06 $1.00 | ▼ −5.66% | ▼ −3.06% | $0.9400 (−11.32%) |
|
May 27, 2026
18d ago
|
8-K
| $1.16 $1.08 | ▼ −6.49% | ▼ −7.05% | $0.9400 (−18.61%) |
|
May 13, 2026
4w ago
|
8-K
| $0.9710 $0.9750 | ▲ +0.41% | ▼ −0.37% | $0.9400 (−3.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access